As shown in Table 3, except for those patients with type 1 diabetes or with eGFR below 20 ml/min, the majority of patients were not prescribed with SGLT-2 inhibitors because of medical concerns about concomitant urologic diseases and/or history of urinary infections (more than 50% when taken together). This evidence concerns the gene SLC5A2 and urinary system disorder.